Effect of Low Molecular Weight Heparin combined with Xingxiong Sodium Chloride in stroke patients complicated with deep vein thrombosis
XING Liang1 TENG Zhipeng1 LUO Chao1 PENG Xing1 HE Yi′na2
1.Department of Neurosurgery, Chongqing Traditional Chinese Medicine Hospital, Chongqing 400021, China;
2.Department of Nephroendocrinology, Chongqing Dongnan Hospital, Chongqing 401336, China
Abstract：Objective To observe the effect of Low Molecular Weight Heparin combined with Xingxiong Sodium Chloride Injection in stroke patients complicated with deep vein thrombosis. Methods From December 2015 to December 2018, 38 stroke patients complicated with deep vein thrombosis in Chongqing Traditional Chinese Medicine Hospital were selected as study subjects. According to the treatment method, they were divided into the control group (21 cases) and the observation group (17 cases). The control group was treated with Low Molecular Weight Heparin Calcium Injection, and the observation group was treated with Xingxiong Sodium Chloride Injection on the basis of the control group. The cure rate of deep vein thrombosis and clinical efficacy were compared between the two groups. Results The cure rate of the observation group was higher than that of the control group, and the difference was statistically significant (P < 0.05). The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P < 0.05). Conclusion Xingxiong Sodium Chloride Injection combined with Low Molecular Weight Heparin can promote the cure rate of deep vein thrombosis and relieve the symptoms more effectively.
[1] Kruger PC，Eikelboom JW，Douketis JD，et al. Deep vein thrombosis：update on diagnosis and management [J]. Med J Aust，2019，210（11）：516-524.
[2] Ji R，Li G，Zhang R，et al. Higher risk of deep vein thrombosis after hemorrhagic stroke than after acute ischemic stroke [J]. J Vasc Nurs，2019，37（1）：18-27.
[3] 中华医学会外科学分会血管外科学组.深静脉血栓形成的诊断和治疗指南（第三版）[J].中华普通外科杂志，2017， 32（9）：807-812.
[4] Pierot L，Jarayaman M，Szikora I，et al. Standards of Practice in Acute Ischemic Stroke Intervention International Recommendations [J]. Can J Neurol Sci，2019，46（3）：269-274.
[5] Suarez JI，Sheikh MK，Macdonald RL，et al. Common Data Elements for Unruptured Intracranial Aneurysms and Subarachnoid Hemorrhage Clinical Research：A National Institute for Neurological Disorders and Stroke and National Library of Medicine Project [J]. Neurocrit Care，2019，30（Suppl 1）：4-19.
[6] Dizon MAM，De Leon JM. Effectiveness of Initiating Deep Vein Thrombosis Prophylaxis in Patients With Stroke：An Integrative Review [J]. J Neurosci Nurs，2018，50（5）：308-312.
[7] Goshgarian C，Gorelick PB. DVT Prevention in Stroke [J]. Curr Neurol Neurosci Rep，2017，17（10）：81.
[8] Stecker M，Michel K，Antaky K，et al. Risk Factors for DVT/PE in Patients with Stroke and Intracranial Hemorrhage [J]. Open Neurol J，2014，8：1-6.
[9] Turner D，Scully M，Stone S，et al. Recurrent brain ischaemia and deep vein thrombosis：the clot thickens [J]. Pract Neurol，2017，17（5）：380-382.
[10] Teasell R，Salbach NM，Foley N，et al. Canadian Stroke Best Practice Recommendations：Rehabilitation，Recovery，and Community Participation following Stroke [J]. Part One：Rehabilitation and Recovery Following Stroke；6th Edition Update 2019. Int J Stroke，2020，15（7）：763-788.
[11] Gittler M，Davis AM. Guidelines for Adult Stroke Rehabilitation and Recovery [J]. JAMA，2018，319（8）：820-821.
[12] Winstein CJ，Stein J，Arena R，et al. Guidelines for Adult Stroke Rehabilitation and Recovery：A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association [J]. Stroke，2016， 47（6）：e98-e169.
[13] Bilora F，Ceresa M，Milan M，et al. The impact of deep vein thrombosis on the risk of subsequent cardiovascular events：a 14-year follow-up study [J]. Int Angiol，2017， 36（2）：156-159.
[14] Waheed SM，Hotwagner DT. Deep Vein Thrombosis （DVT），in Stat Pearls [M]. Treasure Island （FL），2019.
[15] Di Nisio M，Vedovati MC，Riera-Mestre A，et al. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies [J]. Thromb Haemost，2016，116（4）：739-746.
[16] 王巍，王起，孙晓云，刘平.杏芎氯化钠注射液对大鼠局灶性脑缺血再灌注损伤的保护作用[J].中国临床药理学杂志，2018，34（15）：1846-1850.
[17] 任弋，刘鄂湖，兰丽，等.杏芎氯化钠注射液对大鼠脑缺血再灌注损伤的保护作用及机制[J].中国药科大学学报，2015，46（6）：719-723.
[18] 余泽程，雒晓东，蔡巧娣，等.杏芎氯化钠注射液治疗缺血性脑卒中效果与安全性的Meta分析[J].中国医药导报，2019，16（29）：153-157.
[19] 伍志权.杏芎氯化钠注射液治疗缺血性心肌病心力衰竭的临床效果[J].中国当代医药，2019，26（31）：42-44.
[20] 张勇.杏芎氯化钠注射液治疗缺血性心肌病心力衰竭疗效观察[J].北京医学，2017，39（11）：1179-1180.
[21] Franciosiz AN，McCarthy C，Carroll TP，et al. Unusual Acute Sequelae of α1-Antitrypsin Deficiency：A Myriad of Symptoms With One Common Cure [J]. Chest，2015，148（5）：e136-e138.
[22] 王江，刘青.杏芎氯化钠注射液治疗下肢动脉硬化性闭塞症40例[J].中医药临床杂志，2008（2）：167-168.
2020, Vol. 17 
京公网安备 11010502046598号